[{"id":"6e878a86-14bd-474e-806a-2260460e86af","acronym":"VBP301","url":"https://clinicaltrials.gov/study/NCT05984199","created_at":"2023-08-09T14:09:38.757Z","updated_at":"2025-02-25T17:02:46.628Z","phase":"Phase 1/2","brief_title":"Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant","source_id_and_acronym":"NCT05984199 - VBP301","lead_sponsor":"Vor Biopharma","biomarkers":" CD33 • HLA-DRB1","pipe":"","alterations":" ","tags":["CD33 • HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VCAR33ALLO"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/11/2023","start_date":" 12/11/2023","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2025-02-03"}]